An overview of mechanical circulatory support in single-ventricle patients by Miller, Jacob R et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2019 
An overview of mechanical circulatory support in single-ventricle 
patients 
Jacob R Miller 
Timothy S Lancaster 
Connor Callahan 
Aaron M Abarbanell 
Pirooz Eghtesady 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
© Translational Pediatrics. All rights reserved.   Transl Pediatr 2018;7(2):151-161tp.amegroups.com
Introduction
Individuals with single-ventricle physiology comprise a 
complex, and heterogenous, sub-group of patients with 
congenital heart disease (CHD). Palliation to single-
ventricle physiology involves multiple operations eventually 
resulting in passive blood flow to the pulmonary circulation 
with the single-ventricle providing systemic blood flow. 
When cardiac failure develops in these patients, providing 
mechanical circulatory support (MCS) is an especially 
challenging problem due to the altered systemic venous 
return and arterial connections. However, MCS, in the 
form of extracorporeal membrane oxygenation (ECMO) or 
a ventricular assist device (VAD), may represent the only 
alternative to death. While some initial studies have been 
reported, the outcome of single-ventricle patients who 
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require MCS remains unclear.
With improved operative techniques and critical care, 
the single-ventricle population is continually increasing. 
Currently, more than 1,000 new Fontan operations are 
performed annually in the United States and Canada 
alone (1). The first generation of surviving patients with 
Fontan physiology are now well into adulthood (2). 
These numbers include only patients who have reached 
the Fontan stage, and do not include the single-ventricle 
patients currently living at an earlier stage of palliation. As 
the single-ventricle population has increased, heart failure 
in patients with a single-ventricle has become the most 
common indication for heart transplant in children (3). 
Not surprisingly, in correlation, MCS for single-ventricle 
patients has increased, and is only likely to further increase 
in the future (4). Currently, nearly half of all pediatric 
patients who are placed on ECMO for cardiac indications 
have a single-ventricle (5).
ECMO has been utilized extensively in pediatric patients 
due to its speed of initiation, ability to provide both cardiac 
and pulmonary support, ability to support patients of any 
size (except the smallest of neonates), and the ability to 
seamlessly transition from cardiopulmonary bypass (CPB). 
However, survival for patients who require ECMO is poor 
for patients with CHD, and even worse for patients with a 
single-ventricle (5). It is employed to allow for myocardial 
recovery, support until a reparative operation can be 
performed or (more recently) as a bridge to a VAD, and 
potentially as a bridge to decision. ECMO, however, is 
hampered by a significant complication rate that increases 
with the duration of support (6,7). Currently, VADs have 
been increasingly utilized in many pediatric situations (8-13). 
A VAD offers the benefits of a longer duration of support, 
therefore, allowing more time for either recovery or to 
find a suitable donor (14). Therefore, ECMO and VAD 
support should be treated as unique therapies with different 
indications for use.
Importantly, while patients are often considered within 
a single category, “single-ventricle”, they can develop 
cardiac failure at any stage of palliation and at any time 
postoperatively. Therefore, the term “single-ventricle” 
encompasses a heterogenous patient population. Further, 
the mode of failure is often distinct, within each stage of 
palliation and for each patient specifically, making each 
patient with cardiac failure and any form of single-ventricle 
anatomy truly unique. Lastly, due to the small sample sizes, 
ECMO and VADs are often considered together as MCS, 
despite device selection having significant implications on 
the patient’s outcome. 
This review focuses on the current utilization of MCS 
in patients with a single-ventricle. As this is an uncommon 
indication, and each situation is very unique, the data are 
limited, as is the generalizability of the published literature. 
We discuss the overall reported outcomes of MCS in 
single-ventricle patients, the implications of the varied 
cardiac anatomy, MCS device chosen, cannulation strategies 
and technical considerations. Data from the largest existing 
series is cited whenever possible. Case reports or small 
series are used as necessary, though, with appropriate 
consideration of a significant publication bias.
Outcomes
The current data available evaluating the survival of single-
ventricle patients who require MCS are quite limited and 
difficult to interpret. Most consider the survival to hospital 
discharge of single-ventricle patients who require MCS 
to be 30–50% (4,15-18). When evaluating all patients 
with a single-ventricle who underwent MCS over a 
25-year period at a single institution, of 57 patients, 
18 (33%) survived to hospital discharge (16). Considering 
the Berlin Heart EXCORE IDE database, evaluating 
outcomes for single-ventricle patients, survival of 26 patients 
was 42% (4). Utilizing the KID (Kids Inpatient Database) 
to analyze survival in single-ventricle patients who require 
ECMO allowed for an analysis of 701 patients over 10 years; 
overall survival was 43%, and importantly, the outcomes did 
not improve over the decade evaluated (15). Though these 
are the most informative studies available, each evaluated 
the outcomes of a heterogenous patient population, with 
unique anatomy and indications for MCS. Definitively, the 
data does support that single-ventricle patients who require 
ECMO are likely to have poor outcomes, even worse than 
other CHDs (4). Additionally, patients who demonstrate 
any type of end-organ dysfunction prior to MCS initiation 
are more likely to have a poor outcome (9). 
Impact of stage of palliation of single-ventricle physiology
Likely the most important factor impacting the anticipated 
survival for any patient requiring MCS is the stage of 
palliation (19). This is for many reasons, first, being 
that the patient’s current anatomy likely impacts their 
response to MCS (20). Additionally, stage of palliation 
correlates with many factors that likely dictate the patient’s 
outcome including: size, age, available devices, ability to 
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anticoagulate and availability of donors for transplant. In 
addition, possibly the most important factor is indication. 
Clearly a patient who requires ECMO for inability to wean 
from CPB after Norwood is different than an adult with late 
Fontan failure who requires VAD as a bridge to transplant. 
First stage
Patients who require MCS after the first stage of palliation 
are often suffering from post-cardiotomy shock. As 
these patients recover from CPB and adapt to their new 
circulation, MCS may be necessary as a bridge to recovery. 
In these patients, the MCS must provide cardiopulmonary 
support with ECMO or, if only cardiac support, provide 
sufficient flow through the systemic circulation and the 
systemic-pulmonary shunt. In the previously referenced 
studies evaluating the survival for single-ventricle patients 
who received MCS, survival of patients who required MCS 
after their first stage were 32% for patients supported with 
a VAD (16) and 11% when considering the Berlin Heart 
EXCOR IDE database (4).
Most would expect this patient population to have a 
poor survival, as it is essentially selected for neonatal post-
cardiotomy patients who are unable to tolerate their new 
circulation. Indeed, the survival for these patients in the 
reports referenced above is not good. Others, however, 
have reported over 40% survival with MCS utilization after 
stage I of palliation (17). Substantially different results may 
be in part due to device selection, surgical technique or 
postoperative care, however, patient selection is by far the 
most likely factor. Supporting this, when utilized on patients 
who have a repairable problem (usually shunt thrombosis), 
when MCS support is required between stages I and II, 
survival greater than 80% is reported (18). Further, when 
VAD implantation is utilized after every Norwood, even 
in patients who are stable, survival approaches 90% (21). 
Though some might state this as evidence for the 
routine use of MCS after Norwood, much more likely, it 
demonstrates the impact of patient selection. Whether 
indiscriminate use of MCS would improve overall survival 
by providing early assistance to the most difficult patients, 
remains to be seen. 
An additional consideration for post-Norwood patients 
is the type of systemic-pulmonary shunt, Blalock-Taussig 
(BT) or Sano. Though it has never been studied, the type 
of systemic-pulmonary shunt will influence outcomes of 
patients after stage I who require MCS. With a Sano shunt, 
flow through the pulmonary circulation is dependent on 
blood within the failing ventricle, which is diminished in 
a ventricle that is decompressed. We have typically taken 
down the Sano shunt and created a BT shunt at the time 
of VAD implant; or, on occasion, we have disconnected the 
proximal aspect of the Sano and reattached it to the outflow 
graft of the VAD (Figure 1) (22).
Second stage
MCS after the second stage of palliation has the advantage 
of a more efficient anatomy than a Norwood, due to the 
superior cavopulmonary connection (SCPC) supplying 
the pulmonary vasculature in series with the systemic 
circulation (Figure 2). However, with only a SCPC, the 
decompression of the single-ventricle has competing 
implications. Both the VAD augmented cardiac output and 
ventricular decompression act to increase flow through the 
Glenn anastomosis and improve oxygenation. Conversely, 
there will also be an increased flow of deoxygenated blood 
through the inferior vena cava (IVC). The summation has 
been shown in an experimental model to lead to increased 
oxygen delivery (23). Additionally, in case reports, it leads 
to improved hemodynamics (24,25). MCS use after the 
second stage, when considering the previously discussed 
manuscripts, has a survival of 36% for all VADs (16) and 
58% when looking at the Berlin Heart EXCOR IDE 
database (4). These are both very small patient populations, 
11 and 26, respectively.
Figure 1 Cannulation after stage I of palliation utilizing an arterial 
Berlin Heart cannula as outflow placed within the common atrium 
and the Berlin Heart aortic cannula using a Gore-Tex extension 
into the neoaorta. The patient has a Blalock-Taussig shunt.
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Some institutions, feel that patients who deteriorate 
shortly after Glenn are demonstrating their inability to 
tolerate the circulation and that they warrant consideration 
of SCPC takedown and recreation of the systemic-
pulmonary shunt while implanting the VAD (16). These 
sentiments are based on poor outcomes with attempts 
at VAD support immediately post SCPC. Importantly, 
implantation of MCS on the systemic side would not 
address underlying problems with pulmonary vasculature 
or other limitations to pulmonary blood flow that are not 
related to sufficient cardiac output. These patients would 
subsequently require a heart transplant. As much as any, the 
patients who require MCS after SCPC have outcomes that 
remain unknown.
Third stage
For patients with a failing Fontan, when taken as a whole, 
the previously referenced studies noted survival to hospital 
discharge of 40% for any VAD (16) and 60% when 
considering the Berlin Heart EXCOR IDE database (4). 
Inflow cannulation can be performed via the ventricular 
apex (Figure 3A) or the atrium (Figure 3B). The outcomes 
for patients with a failed Fontan must be considered based 
on indication for VAD implant. Certainly, those with 
early Fontan failure are a different patient population than 
those with late Fontan failure. Further, in patients with 
late Fontan failure, the indication for VAD can be either 
impaired ventricular function (IVF) or preserved ventricular 
function (PVF) but with failing Fontan physiology.
Heart failure in the acute postoperative period after 
Fontan has been successfully supported with MCS in 
multiple instances. Some are for patients in the acute 
postoperative Fontan period (26), others for Fontan patients 
who required additional cardiac operations and developed 
Figure 2 Cannulation after stage II of palliation. Similar 
cannulas are utilized as after stage I. The superior cavopulmonary 
anastomosis is demonstrated and the systemic-pulmonary shunt 
has been taken down.
Figure 3 HeartWare HVAD placement in patients with a failing Fontan. (A) The HVAD inflow cannula is placed within the ventricular 
apex with the outflow cannula into the neoaorta; (B) the HVAD inflow cannula is placed into the atrium with the outflow cannula into the 
neoaorta. 
A B
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postcardiotomy shock (27,28). There have been reports of 
successful bridge to recovery postoperatively, after even 
long durations of VAD support (29).
For late failing Fontan, indications typically fall on 
the spectrum between IVF and PVF. Considering VAD 
implant for these two indications, it is unlikely they would 
have similar outcomes with the same support. Patients 
with IVF would be expected to benefit quickly from a VAD 
implanted to support the systemic ventricle, but those with 
a predominately failing physiology may take significantly 
more time to recover. This is what was initially seen with 
heart transplant for failing Fontan, the outcomes for 
patients with IVF were initially superior (30). Though, 
with improved preoperative care, operative techniques and 
postoperative care, it has now been shown that survival after 
heart transplant may now be equivalent (31,32). It has been 
argued that a patient with IVF would do very well with a 
single VAD supporting the systemic circulation, whereas 
a patient with predominately PVF may require support of 
both sides of the circulation, either with two VADs or a 
total artificial heart (TAH). There is insufficient data at this 
point to argue either against or for such approaches; further, 
few patients present with discrete phenotypes of one or the 
other, with significant overlap in most.
These patients who survive into adolescence or 
adulthood but subsequently develop late Fontan failure 
comprise a group that should be expected to have a high 
rate of survival. Indeed, many reports exist demonstrating 
survival to transplant for both PVF (33,34) and IVF (35). 
Considering that the vast majority are case reports, a 
substantial publication bias probably gives a false impression 
of the success rate. Likely one of the main factors leading 
to poor outcomes is the reluctance of the heart failure 
team to pursue VAD implant, either due to unfamiliarity 
of the anatomy or acknowledgement of the increased risk 
associated with the procedure (14). So when MCS is finally 
initiated, the patient is more debilitated than a traditional 
patient who requires VAD implant. Importantly, late failing 
Fontans are a group of patients which will only increase. 
Though the operations for this patient population are quite 
difficult, with appropriate patient selection and timing, 
outcomes should be expected to be quite high.
Device type
Currently, many devices are available to support patients 
with heart failure. The device chosen depends on many 
factors including the indication [anticipated recovery or 
bridge to transplant (BTT)], pulmonary function, anatomy 
and size. In addition, if utilized as a BTT, the anticipated 
duration on the waiting-list is an important factor and, 
therefore, additional factors must be considered such as 
antibody status.
ECMO is the first established MCS. Being comprised 
of both a pump and an oxygenator, it has long been utilized 
to treat patients with cardiorespiratory failure. It remains 
very useful for multiple indications, mainly for its ease 
and speed in initiation/cannulation and termination/
decannulation. It can be initiated using the internal jugular 
and carotid in young children or the femoral artery and 
vein in larger children and adults, or centrally via median 
sternotomy. Additionally, transition from CPB to ECMO is 
quite easy. It does, however, have a significant risk profile, 
with a serious risk of adverse events with any significant 
duration. Due to these attributes it is ideally suited for 
emergencies or support that is anticipated to be of short 
duration (6,7). Limitations of ECMO stem in part from the 
typical required approach: peripheral cannulation generally 
limits flow rates (in contrast to central cannulation) due to 
vessel size, increased surface exposure from long segments 
of an intravascular cannula (and hence greater chance 
for activation of clotting cascades as well as the need for 
anticoagulation), and inherent limitations of mobility and 
rehabilitation potential related to concerns with cannula 
dislodgment. Otherwise ECMO circuitry can be quite 
similar to those commonly used in the pediatric setting with 
temporary devices (see below) with the added oxygenator.
Many pediatric VADs are simply ECMO without the 
oxygenator, such as a CentriMag or PediMag [St. Jude 
Medical Inc. (Thoratec), St. Paul, MN, USA]. Though still 
hampered by many of the disadvantages of ECMO, most 
feel they are far better tolerated with a lower risk of adverse 
events with a longer duration. Patients who have undergone 
an operation may require transition from CPB to a VAD 
of this type for a short period of time to allow for recovery 
from the stress of an operation as well as the adaptation 
to new anatomy (21). Additionally, for patients who 
initially came off bypass, but then developed progressively 
worsening failure, VAD support may prove necessary in the 
acute postoperative period, potentially urgently. ECMO or 
an extracorporeal VAD is ideally suited for these indications.
For longer-term support, a different set of devices has 
emerged as the choice whenever possible. These include 
the Berlin Heart EXCOR (EXCOR) (Berlin Heart, GmbH, 
Berlin, Germany), the HeartMate II (HMII) [St. Jude 
Medical Inc. (Thoratec), St. Paul, MN, USA] and the 
156 Miller et al. MCS in single-ventricle
© Translational Pediatrics. All rights reserved.   Transl Pediatr 2018;7(2):151-161tp.amegroups.com
HeartWare HVAD (HVAD) (HeartWare International, 
Framingham, MA, USA). The EXCOR has shown 
significant utility in pediatric patients in nearly all settings, 
including patients with a single-ventricle (4,9,11,36-38). 
The EXCOR is an extracorporeal pneumatically driven 
pulsatile device with a large controller tower. The HM II 
and the HVAD are much smaller intracorporeal continuous-
flow (CF) devices with easily transported battery packs. 
These CF devices, while originally designed for adults, 
have been used extensively in pediatrics (39,40). Their use 
in patients with a single-ventricle remains quite limited, 
though there are case reports (33-35). In pediatric patients, 
practice has recently shifted to CF devices in patients 
large enough to support one (41). The CF design allows 
for a smaller device, which allows for improved patient 
mobility and rehabilitation. Going forward, the majority 
of devices placed in patients of sufficient size will be a CF 
device.
While not as commonly utilized, some report excellent 
experiences with the Syncardia Total Artificial Heart 
(Syncardia Systems, Tucson, AZ, USA) in pediatric patients, 
and its use has been described in a single-ventricle patient 
(42,43). In a patient with a failing single-ventricle, most 
specifically with failing physiology or a mixed picture, it 
may prove to have significant utility. Theoretically, it could 
allow for the advantages of BiVAD support with improved 
rehabilitation due to the increased mobility over two 
devices. Indeed, its use has been described successfully in a 
patient with failing Fontan physiology (43).
We advocate for the use of an intracorporeal VAD 
whenever possible, for multiple reasons including, the 
demonstrated improved outcomes in other populations, 
the improved ability for rehabilitation and the improved 
quality of life (8,9,11,16,44). The Berlin Heart EXCOR 
may be necessary if the patient is small, but if the patient 
is large enough [body surface area (BSA) is >1 m2], a CF 
VAD should be used. We prefer the HeartWare HVAD 
due to its size. In the patient who is acutely postoperative, 
either unable to wean from bypass or deteriorates in the 
acute postoperative period, we recommend transition from 
CPB to ECMO or VAD such as the PediMag (depending 
on pulmonary function). If postoperative failure develops 
suddenly and requires urgent MCS, ECMO should be 
initiated peripherally. However, once it is determined 
that there is no pulmonary pathology, the patient should 
be converted to a VAD to allow for recovery or BTT. 
Specifically, we attempt to avoid the use of an oxygenator 
whenever possible (45).
Configuration
When utilizing MCS in a patient with a single-ventricle, the 
patient’s anatomy and pathology must both be considered 
so that the MCS is used optimally. Patients with a single-
ventricle fail due to failure of the ventricle to support 
the systemic circulation (or systemic and pulmonary in a 
shunted patient), or due to their inability to tolerate their 
passive pulmonary circulation. Therefore, the selection 
of the device configuration is likely the most important 
controllable factor, with the exception of whether or not 
to utilize MCS at all. Multiple configurations are possible, 
systemic VAD placement, VAD support for only the 
pulmonary circulation and BiVAD or TAH support, all of 
which have been described.
When supporting patients after stage 1 of palliation, 
the device must provide flow to support both the systemic 
and pulmonary circulation. We have recently come to 
prefer a cannulation technique which utilizes the common 
atrium for inflow and the neoaorta as outflow (22). In our 
experience, we have found cannula selection to be very 
important in limiting thrombus formation. For the inflow, 
we prefer the arterial Berlin Heart cannula due to its smaller 
surface within the atrium and lower likelihood of creating 
stagnant flow. The outflow cannula is the Berlin Heart aortic 
cannula with either a homograft or Gore-Tex (W.L. Gore 
and Associates, Elkton, MD, USA) extension. If the patient 
has a Sano shunt, this is taken down. To provide pulmonary 
flow, either a BT shunt is created or the proximal end of 
the Sano shunt is anastomosed end-to-side to the outflow 
cannula via the homograft or Gore-Tex extension (45).
For patients after Fontan, the vast majority of patients 
who receive VAD support, receive support of the systemic 
ventricle. In a patient with IVF without other signs of 
failure, this is the ideal treatment option. However, for 
patients with failing physiology, or a more mixed picture, 
the decision is more difficult. Our bias is that a single VAD 
supporting the systemic ventricle will allow for improved 
physiology as we believe all of these patients suffer from a 
substantial, and under-appreciated, collateral burden that 
“steals” 20–50% of cardiac output (and in turn an increased 
volume load that burdens the single ventricle), in addition 
to addressing any other underlying pulmonary circulation 
issues, despite absence of hemodynamic significance 
(i.e., if there is no gradient by angiography demonstrates 
suboptimal anatomy). We do not believe that pulmonary 
blood flow can be augmented by “sucking” it across the 
pulmonary vascular bed. A decrease in central venous 
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pressure upon initiation of inotropic support demonstrates 
the potential benefit of a VAD for these patients. Some 
have argued that support of both the systemic ventricle and 
the right side may be superior, especially if the elevated 
pulmonary pressures are thought unlikely to be “reversible”. 
It is hard to believe that these same patients, not too long 
ago, were deemed to have low enough pulmonary pressures 
to undergo Fontan palliation. Nevertheless, it has been 
shown that a single right sided VAD may be sufficient for 
some patients (46). However, placement of a right sided 
VAD may be technically quite challenging.
BiVAD support has been described in the failing Fontan 
patient (47). Though some feel that the addition of a 
second VAD increases the risk of complications, it has been 
shown that BiVAD support can be done without increased 
risk (9,11,48). Implantation of a second pump does, 
however, increase the surgical complexity of an already 
difficult operation. Further, the disadvantage of impaired 
rehabilitation due to a second device may have significant 
implications. Though, if necessary, not providing support 
for the pulmonary circulation would leave the patient 
debilitated, clearly a worse alternative.
Technical difficulties
Utilization of MCS in patients with a single-ventricle 
is a surgical challenge. These patients require a redo-
sternotomy, often times multiple, with what can be a 
difficult dissection. Patients often have foreign material 
present, either a Fontan conduit or a systemic-pulmonary 
shunt. Injury to any native or foreign structures may have 
catastrophic implications. Further, if a cardiac chamber is 
inadvertently entered during dissection prior to cross-clamp 
application, an air embolism is possible. In addition, these 
patients commonly have substantial collateral flow, which 
can complicate the dissection prior to CPB and impair 
visualization once on bypass. Regardless of the configuration 
of VAD support chosen, sternal entry and the dissection 
process may be difficult in these patients. For that reason, 
in our population of multiple redo-sternotomies a femoral 
arterial and venous line are placed prior to incision. These 
lines are large enough to accept a wire for percutaneous 
CPB initiation if it becomes emergently necessary.
For patients who are going to have a VAD implanted, 
inflow cannula placement is more complex than in a normal 
ventricle. The inflow can be placed in either the apex of 
the ventricle or the atrium. Placement within the apex is 
more familiar to most surgeons but may require significant 
trabecular resection. Atrial placement avoids the difficulties 
with trabeculations, but the inherent lack of strength in 
the atrial wall does create concerns for suck down events. 
Single-ventricle patients may have a single right ventricle, 
which will undoubtedly have more-dense trabeculations 
than a single left ventricle. Further, as the ventricle dilates, 
the apex can be displaced, making it difficult to identify. As 
the geometry of the single-ventricle dilates and changes, 
the angle of the inflow cannula may be difficult to predict. 
There have been multiple reports of VAD implants into 
the systemic right ventricle of patients with dextro-
transposition of the great arteries (D-TGA) after atrial 
switch (49-51) or in congenitally corrected TGA (CC-TGA) 
(52-54). In many, apical inflow cannula placement is aided 
by use of a needle with transesophageal echocardiographic 
guidance (55-57). This will allow the cannula to be far 
enough from the septum and atrioventricular valve to 
avoid suck down events. In pediatric patients, especially if 
the ventricular muscle is thinned, the depth of the inflow 
cannula can be decreased by placing multiple felt rings on 
the epicardium (35). This latter approach has also been taken 
with cannulation of the common atrium using the HVAD, 
successfully bridging Fontan patients to transplant (58).
For patients who do require right sided support, usually, 
significant surgical reconstruction is necessary; a capacitance 
chamber may need to be constructed to accommodate the 
inflow cannula. This chamber must be created from the 
already surgically manipulated superior vena cava (SVC) 
and IVC. Outflow cannula placement is into the pulmonary 
arteries, which also require reconstruction. This significantly 
increases the operative and bypass time and the surgical risk. 
As an alternative to BiVAD support, a TAH can be utilized. In 
this instance, the operative difficulty revolves around returning 
the systemic venous return to the right atrium, which may 
need reconstruction, again a major operation (43). 
Future directions
ECMO utilization has been shown to be increasing as a 
percentage of hospitalizations for patients with a single-
ventricle (4). In addition, the population of patients who 
exist with a single-ventricle is continuing to increase. 
Knowing that a certain percentage of these Fontan patients 
will eventual fail means that, going forward, an increasing 
number of VADs will be implanted in patients with a 
single-ventricle. As many of these will be placed as a BTT, 
improved timing and patient selection of VAD implantation 
will become crucial. To accomplish this, risk factors for a 
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poor outcome need to be more clearly delineated. To that 
end, a registry was created to identify the risk factors and 
evaluate the outcomes of patients with a single-ventricle 
who require MCS (59).
For these complicated patients, going forward, computer 
models have been developed (60). Using computer models, 
a simulator has been created to allow for the simulation of 
a surgical procedure to evaluate the impact of operations 
at all three stages of palliation (61). These, and other, 
computer models can be used demonstrate the impact of 
MCS utilization in patients with different anatomy (20). As 
the number of patients treated increases, these models could 
potentially become more accurate and robust. Theoretically, 
these could be used to simulate different devices placed 
in different configurations. This could have a significant 
impact on preoperative planning.
In patients with single-ventricle and other complex 
CHDs, three-dimensional (3D) printing has been utilized 
in some of the most difficult scenarios (62,63). It provides 
the spatial orientation to potentially improve preoperative 
planning. Further, it is a useful tool to aid communication 
with the patient and family, cardiologists and critical care 
team (64). It has shown utility in allowing for preoperative 
planning of inflow cannula placement when faced with 
the challenges of implanting a VAD into a systemic right 
ventricle (65). Going forward, it may be utilized with more 
frequency with these complex cases.
For Fontan patients, a unique device has been proposed, 
and tested in an animal model, a viscous impeller pump 
(VIP) (66). This device is inserted transvenous and is placed 
at the junction of the SVC/IVC and PAs (67). As the device 
rotates, the right sided pressure is augmented and cardiac 
output is improved (68). It could be used in the failing 
Fontan, specifically for patients with failing physiology. 
This could provide temporary support to improve the end-
organ function in a patient prior to transplant (69). Further, 
it could improve patient selection by identifying those who 
recover end-organ function, presumably a marker for a 
good outcome post-heart transplant. Currently the use of 
this device is preclinical.
There are new devices on the horizon in the adult 
population that could be brought into the pediatric realm. 
Recently the relatively new HeartMate 3 device [St. Jude 
Medical Inc. (Thoratec)] has shown promise, with improved 
6-month outcomes compared to the HM II, and has a size 
more comparable to the HVAD (70). The HeartWare 
MVAD is another device that initially showed promise, 
especially with its very small size, however, it is not yet 
available. Finally, the PumpKIN trial continues testing of 
the Jarvik 2015, a CF device which could support even the 
smallest of patients (71).
Certainly, in all centers where MCS is utilized in patients 
with a single-ventricle (either pediatric or adult), experts 
in every field must be readily available. Others have noted 
the benefits of a multidisciplinary approach consisting 
of surgeons and heart failure specialists, intensivists, 
hematologists, pharmacists, nurses and potentially 
psychiatrists and infectious disease physicians (72). We feel 
this is absolutely necessary to optimize the outcomes of 
these very difficult patients.
Conclusions
Patients with a single-ventricle comprise a heterogenous 
and inherently difficult patient population. When their 
condition necessitates the initiation of MCS, currently, their 
outcome is difficult to predict. Further studies are needed 
evaluating unique cannulation strategies, outcomes based on 
stage of palliation, patient selection and timing of MCS. A 
registry has been created to aid in answering these questions 
in the future (59).
The number of single-ventricle patients who require 
MCS is going to increase as the overall single-ventricle 
population increases. As patients with a failing single-
ventricle age and an inevitable portion develops heart 
failure, some have dubbed a heart transplant the “fourth 
stage” (73). Likely, many of these patients will be considered 
at some point for possible VAD support. Though currently 
the outcomes are poor, there is promise, that with improved 
devices, increased experience and the development of risk 
factors to improve patient selection and operative timing, 
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